PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH ), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care. Germline genetic testing is recommended by medical practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. 1 The testing analyzes inherited genetic variants, typically present in all the cells of the body, that may predispose an individual to certain risks or diagnoses, including hereditary cancers and other genetic conditions.